

ACTA MEDICINAE 8/2014 Onkologie

Kompletní literatura

- 2 **Predikce incidence a prevalence nádorových onemocnění a počtu léčených onkologických pacientů v ČR v letech 2015 a 2020**
doc. RNDr. Ladislav Dušek, Ph.D. Institut biostatistiky a analýz, Lékařská fakulta Masarykovy univerzity, Brno, Ústav zdravotnických informací a statistiky ČR, Praha RNDr. Tomáš Pavlík, Ph.D. | RNDr. Ondřej Májek, Ph.D. | Mgr. Jakub Gregor, Ph.D. IBA, LF MU, Brno RNDr. Jan Mužík, Ph.D. IBA, LF MU, Brno, ÚZIS ČR, Praha RNDr. Denisa Malúšková | Mgr. Jana Koptíková, Ph.D. | Mgr. Zbyněk Bortlíček IBA, LF MU, Brno prof. MUDr. Jitka Abrahámová, DrSc. Thomayerova nemocnice, Praha
- 2 **Predikce počtu pacientů indikovaných k vyšetření PET/CT v ČR: první výsledky projektu PET/CT-CZ[®]**
doc. RNDr. Ladislav Dušek, Ph.D. Institut biostatistiky a analýz, Lékařská fakulta Masarykovy univerzity, Brno, Ústav zdravotnických informací a statistiky ČR, Praha prof. MUDr. Jiří Petera, Ph.D. | doc. MUDr. Jiří Doležal, Ph.D. Fakultní nemocnice Hradec Králové prof. MUDr. Vlastimil Válek, CSc. Fakultní nemocnice Brno RNDr. Tomáš Pavlík, Ph.D. | RNDr. Ondřej Májek, Ph.D. Institut biostatistiky a analýz, Lékařská fakulta Masarykovy univerzity, Brno Mgr. Michal Burger Institut biostatistiky a analýz, Lékařská fakulta Masarykovy univerzity, Brno, Ústav zdravotnických informací a statistiky ČR, Praha Mgr. Jakub Gregor, Ph.D. | Mgr. Jana Koptíková, Ph.D. Institut biostatistiky a analýz, Lékařská fakulta Masarykovy univerzity, Brno RNDr. Jan Mužík, Ph.D. Institut biostatistiky a analýz, Lékařská fakulta Masarykovy univerzity, Brno, Ústav zdravotnických informací a statistiky ČR, Praha
- 3 **Doporučení pro léčbu sarkomů měkkých tkání Evropské společnosti klinické onkologie, ESMO**
MUDr. Kateřina Kubáčková Onkologická klinika 2. LF UK a FN Motol, Praha
- 3 **Novinky v hormonální léčbě karcinomu prsu před a po ASCO 2014**
prof. MUDr. Luboš Petruželka, CSc. | MUDr. Zuzana Ušiaková | MUDr. Michal Vočka | MUDr. Lucie Hussarová Onkologická klinika 1. LF UK a VFN v Praze a Ústřední vojenská nemocnice – Vojenská fakultní nemocnice Praha, Ústav radiační onkologie Nemocnice Na Bulovce v Praze
- 3 **Antracykliny v první linii léčby karcinomu prsu mohou být účinnější, než si myslíme – kazuistika**
doc. MUDr. Petra Tesařová, CSc. Onkologická klinika 1. LF UK a VFN v Praze
- 4 **Nemalobuněčný karcinom plic – novinky v léčbě**
prof. MUDr. Jana Skříčková, CSc. | MUDr. Ondřej Venclíček | MUDr. Bohdan Kadlec, Ph.D. | MUDr. Marcela Tomíšková | MUDr. Lenka Jakubíková, Ph.D. | Jana Špaldová
Klinika nemocí plicních a tuberkulózy LF MU a FN Brno
- 4 **Nemalobuněčný karcinom plic s přestavbou genu EML4-ALK – nové možnosti léčby**
prof. MUDr. Miloš Pešek, CSc. Klinika tuberkulózy a respiračních nemocí FN Plzeň
prof. Dr. med. Michael Hilker, FETCS Universitätsklinikum Regensburg, Německo
RNDr. Petr Grossmann FN Plzeň, Šiklův patologicko-anatomický ústav Plzeň
- 5 **Možnosti systémové léčby gastroenteropankreatických neuroendokrinních tumorů**
MUDr. Jiří Tomášek, Ph.D. Klinika komplexní onkologické péče MOÚ Brno, LF MU, Brno
- 5 **Gastrointestinální stromální tumor – základní algoritmus diagnostiky a léčby**
MUDr. Zdeněk Linke Onkologická klinika FN Motol a 2. LF UK, Praha
- 6 **Výběr optimální sekvence v léčbě metastatického renálního karcinomu**
MUDr. Hana Študentová Onkologická klinika FN Olomouc
- 6 **Karcinom ovaria – současnost a novinky v léčbě**
MUDr. Josef Chovanec, Ph.D. Oddělení gynekologické onkologie, MOÚ Brno
- 6 **Stanovení strategie léčby u metastatického melanomu**
MUDr. Eugen Kubala Klinika onkologie a radioterapie LF UK a FN Hradec Králové
- 7 **Role parenterální výživy v podpůrné onkologické léčbě – nový pohled**
MUDr. Petr Beneš Interní oddělení, Nemocnice Na Homolce, Praha
- 7 **Novinky v léčbě průlomové bolesti**
MUDr. Marek Hakl, Ph.D. Centrum pro léčbu bolesti ARK LF MU a FN u sv. Anny v Brně
- 7 **Qutenza v léčbě chemoterapií indukované polyneuropatie**
MUDr. Marek Hakl, Ph.D. Centrum pro léčbu bolesti ARK LF MU a FN u sv. Anny v Brně
- 7 **HPV infekce u mužů**
doc. MUDr. Tomáš Fait, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a VFN Praha

Predikce incidence a prevalence nádorových onemocnění a počtu léčených onkologických pacientů v ČR v letech 2015 a 2020

doc. RNDr. Ladislav Dušek, Ph.D. Institut biostatistiky a analýz, Lékařská fakulta Masarykovy univerzity, Brno, Ústav zdravotnických informací a statistiky ČR, Praha RNDr. Tomáš Pavlík, Ph.D. | RNDr. Ondřej Májek, Ph.D. | Mgr. Jakub Gregor, Ph.D. IBA, LF MU, Brno RNDr. Jan Mužík, Ph.D. IBA, LF MU, Brno, ÚZIS ČR, Praha RNDr. Denisa Malúšková | Mgr. Jana Koptíková, Ph.D. | Mgr. Zbyněk Bortlíček IBA, LF MU, Brno prof. MUDr. Jitka Abrahámová, DrSc. Thomayerova nemocnice, Praha

- 1 Curado, M. P. – Edwards, B. – Shin, H. R., et al. (eds.): Cancer incidence in five continents, roč. IX. IARC Scientific Publications č. 160. International Agency for Research on Cancer, Lyon, 2007, vyhledáno 8. 5. 2014, dostupné z: <http://cis.iarc.fr>.
- 2 Ferlay, J. – Soerjomataram, I. – Ervik, M., et al.: GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase č. 11 [internet]. International agency for research on cancer, Lyon, 2013. Vyhledáno 5. 6. 2014, dostupné z: <http://globocan.iarc.fr>.
- 3 Dušek, L. – Mužík, J. – Kubásek, M., et al.: Epidemiology of malignant tumors in the Czech Republic [internet]. Masaryk University, Brno, 2005, vyhledáno 8. 5. 2014, dostupné z: <http://www.svod.cz>.
- 4 Clerc, L. – Jooste, V. – Lejeune, C., et al.: Cost of care of colorectal cancers according to health care patterns and stage at diagnosis in France. *Eur J Health Econ*, 2008, 9, s. 361–367.
- 5 Pavlík, T. – Májek, O. – Mužík, J., et al.: Estimating the number of colorectal cancer patients treated with anti-tumour therapy in 2015: the analysis of the Czech National Cancer Registry. *BMC Public Health*, 2012, 12, s. 117.
- 6 Maddams, J. – Utley, M. – Miller, H.: Projections of cancer prevalence in the United Kingdom, 2010–2040. *Br J Cancer*, 2012, 107, s. 1195–1202.
- 7 Mariotto, A. B. – Yabroff, K. R. – Sbal, Y., et al.: Projections of the cost of cancer care in the United States: 2010–2020. *J Natl Cancer Inst*, 2011, 103, s. 117–128.
- 8 Travis, L. B.: The epidemiology of second primary cancers. *Cancer Epidemiol Biomarkers Prev*, 2006, 15, s. 2020–2026.

Predikce počtu pacientů indikovaných k vyšetření PET/CT v ČR: první výsledky projektu PET/CT-CZ^(Q)

doc. RNDr. Ladislav Dušek, Ph.D. Institut biostatistiky a analýz, Lékařská fakulta Masarykovy univerzity, Brno, Ústav zdravotnických informací a statistiky ČR, Praha prof. MUDr. Jiří Petera, Ph.D. | doc. MUDr. Jiří Doležal, Ph.D. Fakultní nemocnice Hradec Králové prof. MUDr. Vlastimil Válek, CSc. Fakultní nemocnice Brno RNDr. Tomáš Pavlík, Ph.D. | RNDr. Ondřej Májek, Ph.D. Institut biostatistiky a analýz, Lékařská fakulta Masarykovy univerzity, Brno Mgr. Michal Burger Institut biostatistiky a analýz, Lékařská fakulta Masarykovy univerzity, Brno, Ústav zdravotnických informací a statistiky ČR, Praha Mgr. Jakub Gregor, Ph.D. | Mgr. Jana Koptíková, Ph.D. Institut biostatistiky a analýz, Lékařská fakulta Masarykovy univerzity, Brno RNDr. Jan Mužík, Ph.D. Institut biostatistiky a analýz, Lékařská fakulta Masarykovy univerzity, Brno, Ústav zdravotnických informací a statistiky ČR, Praha

- 1 Dušek, L. – Mužík, J. – Kubásek, M. – Koptíková, J. – Žaloudík, J. – Vyzula R.: SVOD.cz – Epidemiologie zhoubných nádorů v České republice (internetová stránka). Masarykova univerzita, 2007, vyhledáno 3. 7. 2014, dostupné na www.svod.cz.
- 2 Ferlay, J. – Autier, P. – Boniol, M. – Heanue, M. – Colombet, M. – Boyle, P.: Estimates of the cancer incidence and mortality in Europe in 2006. *Ann Oncol*, 2007, 18, s. 581–592.
- 3 Ferlay, J. – Steliarova-Foucher, E. – Lortet-Tieulent, J. – Rosso, S. – Coebergh, J. W. – Comber, H., et al.: Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. *Eur J Cancer*, 2013, 49, s. 1374–1403.
- 4 Dyba, T. – Hakulinen, T.: Comparison of different approaches to incidence prediction based on simple interpolation techniques. *Stat Med*, 2000, 19, s. 1741–1752.
- 5 Verdecchia, A. – De Angelis, G. – Capocaccia, R.: Estimation and projections of cancer prevalence from cancer registry data. *Stat Med*, 2002, 21, s. 3511–3526.
- 6 De Angelis, R. – Sant, M. – Coleman, M. P. – Francisci, S. – Baili, P. – Pierannunzio, D., et al.: Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5-a population-based study. *Lancet Oncol*, 2014, 15, s. 23–34.
- 7 Warren, J. L. – Klabunde, C. N. – Schrag, D. – Bach, P. B. – Riley, G. F.: Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. *Med Care*, 2002, 40 (dopl.), s. IV-3-18.
- 8 Czernin, J. – Allen-Auerbach, M. – Schelbert, H. R.: Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. *J Nucl Med*, 2007, 48, dopl. 1, s. 785-885.
- 9 Czernin, J. – Allen-Auerbach, M. – Nathanson, D. – Herrmann, K.: PET/CT in Oncology: Current Status and Perspectives. *Curr Radiol Rep*, 2013, 1, s. 177–190.
- 10 Farwell, M. D. – Pryma, D. A. – Mankoff, D. A.: PET/CT imaging in cancer: Current applications and future directions. *Cancer*, 19. 6. 2014.
- 11 Umbeh, M. H. – Muntener, M. – Hany, T. – Sulser, T. – Bachmann, L. M.: The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. *Eur Urol*, 2013, 64, s. 106–117.
- 12 Ferda, J. – Kastner, J. – Ferdová, E. – Mírka, H. – Hora, M. – Hes, O., et al.: Zobrazení karcinomu prostaty na molekulární úrovni – naše zkušenosti. *Ces Radiol*, 2012, 66, s. 289–295.
- 13 Dušek, L., et al.: Czech cancer care in numbers 2008–2009. Praha, Grada Publishing, 2009.
- 14 Blaha, M. – Janča, D. – Klika, P. – Mužík, J. – Dušek, L.: Project I-COP – architecture of software tool for decision support in oncology. In: Blobel, B. – Hasman, A. – Zvárová, J. (eds.): Data and knowledge for medical decision support: Proceedings of the EFMI special topic conference, 17–19 April 2013, Prague, Czech Republic: IOS Press; 2013.
- 15 Pavlík, T. – Májek, O. – Mužík, J., et al.: Estimating the number of colorectal cancer patients treated with anti-tumour therapy in 2015: the analysis of the Czech National Cancer Registry. *BMC Public Health*, 2012, 12, s. 117.

Doporučení pro léčbu sarkomů měkkých tkání Evropské společnosti klinické onkologie, ESMO

MUDr. Kateřina Kubáčková Onkologická klinika 2. LF UK a FN Motol, Praha

- 1 ESMO/European Sarcomas Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, 2012, 23 (7), s. vii92–vii99.

Novinky v hormonální léčbě karcinomu prsu před a po ASCO 2014

prof. MUDr. Luboš Petruželka, CSc. | MUDr. Zuzana Ušiaková | MUDr. Michal Vočka | MUDr. Lucie Hussarová Onkologická klinika 1. LF UK a VFN v Praze a Ústřední vojenská nemocnice – Vojenská fakultní nemocnice Praha, Ústav radiační onkologie Nemocnice Na Bulovce v Praze

- 1 ASCO Annual Meeting Abstracts, 30. května – 3. června 2014.
- 2 **Bachelot, T., et al.**: Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. *J Clin Oncol*, 2012, 30, s. 2718–2724.
- 3 **Baselga, J., et al.**: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *N Engl J Med*, 2012.
- 4 **Di Leo, A. – Jerusalem, G. – Petruželka, L., et al.**: Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. *J Clin Oncol*, 2010.
- 5 **Jones, S. E., et al.**: Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. *J Clin Oncol*, 2005.
- 6 **Kaufman, B., et al.**: Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TANDEM study. *J Clin Oncol*, 2009.
- 7 **Ellis, M. J., et al.**: Whole-genome analysis informs breast cancer response to aromatase inhibition. *Nature*, 2012.
- 8 **Finek, J. – Petruželka, L., et al.**: První česko-moravský konsensus hormonální léčby karcinomu prsu. 2014 (v přípravě k tisku).
- 9 **Finn, R. S., et al.**: PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. *Breast Cancer Res*, 2009.
- 10 **Finn, R. S., et al.**: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs. letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18). *AACR*, abstrakt CT101, 2014.
- 11 **Giordano, S. H., et al.**: Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol*, 2014.
- 12 **Hober, J., et al.**: Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer—results of the eLECTRA trial. *Breast*, 2012.
- 13 **Jerusalem, G., et al.**: Safety analysis of BOLERO-3: a phase 3 trial of daily everolimus (EVE) vs. placebo (PBO), both with weekly trastuzumab (TRAS) and vinorelbine in trastuzumab-resistant, advanced breast cancer. San Antonio Breast Cancer Symposium; abstrakt S2-02, 2013.
- 14 **Lee, A. V. – Davidson, N. E.**: Genomics, drug approval, and optimal treatment duration. *Nat Rev Clin Oncol*, 2014.
- 15 **Martin, M., et al.**: S1-7. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer—First efficacy results from the LEA study. *Cancer Res*, 2012.
- 16 **Montemurro, M., et al.**: Human epidermal growth factor receptor 2 (HER2) positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. *Ann Oncol*, 2013.
- 17 **Palmieri, C., et al.**: Breast cancer: Current and future endocrine therapies. *Molecular and Cellular Endocrinology*, 2014.
- 18 **Petruželka, L. – Vočka, M. – Matějů, M.**: Metastazující hormonálně dependentní karcinomy prsu – doporučené postupy nebo jen obecné léčebné principy ve světle nových poznatků? 2014.
- 19 **Piccatt, M., et al.**: Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO-2 phase III trial [abstrakt 559]. *J Clin Oncol*, 2012.
- 20 **Piccatt, M., et al.**: Everolimus plus exemestane for hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (BC): overall survival results from BOLERO-2. Přednáška, abstrakt LBA1. European Breast Cancer Conference (EBCC-9), 2014.
- 21 **Swain, S. M., et al.**: Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. *Lancet Oncol*, 2013.
- 22 **Seidman, A. D., et al.**: Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of Cancer and Leukemia Group B protocol 9840. *J Clin Oncol*, 2008.
- 23 **Schwartzberg, L. S., et al.**: Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. *Oncologist*, 2010.
- 24 **Yardley, D. A., et al.**: Results of ENCORE 301, a randomized, phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive (ER+) breast cancer progressing on a nonsteroidal aromatase inhibitor (AI). *J Clin Oncol*, 2013.
- 25 **Yardley, D. A., et al.**: Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium. *Clin Breast Cancer*, 2011.
- 26 **Moore, H. C. F.**: abstrakt LBA505, prezentováno na ASCO Annual Meeting, 30. 5. – 3. 6. 2014, Chicago.
- 27 **Pagani, O. – Regan, M. M. – Walley, B. – Fleming, G. F. – Colleoni, M. – Lang, I. – Gomez, H. L. – Tondini, C. – Burstein, H. J., et al.**: Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials. *J Clin Oncol*, 2014, 32, abstrakt LBA1.
- 28 **Piccatt, M.**: abstrakt LBA9200, prezentováno na ASCO Annual Meeting, 30. 5. – 3. 6. 2014, Chicago.
- 29 **Hortobagyi, G. N.**: abstrakt LBA9500, prezentováno na ASCO Annual Meeting, 30. 5. – 3. 6. 2014, Chicago.

Antracykliny v první linii léčby karcinomu prsu mohou být účinnější, než si myslíme – kazuistika

doc. MUDr. Petra Tesařová, CSc. Onkologická klinika 1. LF UK a VFN v Praze

- 1 **Gennari, A. – D'Amico, M.**: Anthracyclines in the management of metastatic breast cancer: state of the art. *EJC supplements* 9, 2011, 2, s. 11–15.
- 2 **Rivera, E.**: Liposomal anthracyclines in metastatic breast cancer: clinical update. *Oncologist*, 2003, 8, dopl. 2, s. 3–9.
- 3 **Gennari, A. – Piccinino, M. – Sarti, S.**: The role of liposomal anthracyclines in metastatic breast cancer. *Current Breast Cancer Reports*, 2013, 5, s. 23–30.
- 4 **Doval, D. C. – Dutta, K. – Batra, U. – Talwar, V.**: Neoadjuvant chemotherapy in breast cancer: review of literature. *J Indian Med Assoc*, 2013, 111, s. 629–631.
- 5 **Lyseng-Williamson, K. A. – Duggan, S. T. – Kratiny, G. M.**: Pegylated liposomal doxorubicin: a guide to its use in various malignancies. *BioDrugs*, 2013, 27, s. 533–540.

Nemalobuněčný karcinom plic – novinky v léčbě

prof. MUDr. Jana Skříčková, CSc. | MUDr. Ondřej Venclíček | MUDr. Bohdan Kadlec, Ph.D. |
MUDr. Marcela Tomíšková | MUDr. Lenka Jakubíková, Ph.D. | Jana Špaldová

Klinika nemocí plicních a tuberkulózy LF MU a FN Brno

- 1 Dušek, L. – Májek, O. – Mužík, J. – Kostíková, J. – Pavlík, T. – Skříčková, J.: Epidemiologie zhoubných nádorů plic, průdušnice a průdušek v ČR. In: Skříčková, J. – Kolek, V., et al.: *Základy moderní pneumoonkologie*. Maxdorf, Praha, 2012.
- 2 Giroux, D. J. – Rami-Porta, R. – Chansky, K., et al.: The IASLC Lung Cancer Staging Project: data elements for the prospective project. *J Thorac Oncol*, 2009, 4, s. 679–83.
- 3 Pešek, M.: *Nemalobuněčný karcinom plic*. EUNI, dostupné z: <http://www.euni.cz/tema.php?>, vyhledáno 22. 9. 2014.
- 4 Škarda, J. – Überall, I. – Tichý, T. – Matěj, R.: Novinky v klasifikaci adenokarcinomů plic a potenciální prognostické a prediktivní faktory u nemalobuněčných plicních karcinomů. *Cesk Patol*, 2011, 47, s. 168–172.
- 5 Travis, W. D. – Brambilla, E. – Noguchi, M., et al.: International association for the study of lung cancer / american thoracic society / european respiratory society international multidisciplinary classification of lung adenocarcinoma. *J Thorac Oncol*, 2011, 6, s. 244–285.
- 6 Skříčková, J. – Kolek, V., et al.: *Základy moderní pneumoonkologie*. Maxdorf, Praha, 2012.
- 7 Paz-Ares, L. – de Marinis, F., et al.: Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. *Lancet Oncol*, 2012, 13, s. 247–255.
- 8 Lusch, T. J. – Bell, D. W. – Sordella, R., et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med*, 2004, 350, s. 2129–2139.
- 9 Bonomi, P.: Clinical studies with non-irres EGFR tyrosine kinase inhibitors. *Lung Cancer*, 2003, 41, s. S43–S48.
- 10 Duffield, E. L. – Watkins, C. L. – Armour, A. A. – Fukuoka, M.: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *New England Journal of Medicine*, 2009, 361, s. 947–957.
- 11 Kim, E. S. – Hirsch, V. – Mok, T., et al.: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer: a randomised Phase III trial (INTEREST). *Lancet*, 2008, 372, s. 1809–1818.
- 12 Pešek, M.: *Nemalobuněčný karcin plic*. EUNI, dostupné z: <http://www.euni.cz/tema.php?>, vyhledáno 22. 9. 2014.
- 13 Thatcher, N. – Chány, A. – Parikh, P., et al.: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). *Lancet*, 2005, 366, s. 1527–1537.
- 14 Shepherd, F. A. – Pereira, J. R. – Ciuleanu, T., et al.: Erlotinib in previously treated non-small-cell lung cancer. *N Engl J Med*, 2005, 353, s. 123–132.
- 15 Pešek, M. – Skříčková, J. – Kolek, V., et al.: Výsledky klinického hodnocení účinnosti a toxicity gefitinibu v rámci programu časného přístupu u nemalobuněčného karcinomu plic v ČR. *Stud Pneumol Phthiseol*, 2009, 69, s. 62–68.
- 16 Yang, J. Ch. – Schuler, M. – Yamamoto, N. – O'Byrne, K. – Hirsh, V. – Mok, T., et al.: LUX-Lung 3: a randomized, open-label, Phase III study of afatinib vs cisplatin/pemetrexed as 1st-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. *J Clin Oncol*, 2012, 30, dopl., abstrakt LBA7500.
- 17 Wu, Y.-L.: LUX-Lung 6: A randomized, open-label, Phase III study of afatinib (A) vs. gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. American Society of Clinical Oncology, Chicago, 2. 6. 2013. *J Clin Oncol*, 2013, 31, dopl.; abstrakt 8016.
- 18 Yang, L. V. – Sequist, M. – Schuler, T. – Mok, N. – Yamamoto, K. – O'Byrne, V. – Hirsh, S. – Geater, C. – Zhou, D. – Massey, V. – Zazulina, Y.-L.: Overall survival in patients with advanced NSCLC harboring common (Del19/L858R) EGFR mutations: analysis of two large, open-label phase III studies of afatinib vs chemotherapy, LUX-Lung 3 and LUX-Lung 6. ASCO 2014.
- 19 Soda, M. – Choi, Y. L. – Enomoto, M., et al.: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature*, 2007, 448, s. 561–566. Wong, D. W. – Leung, E. L. – So, K. K., et al.: The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. *Cancer*, 2009, 115, s. 1723–1733.
- 20 Shaw, A. T. – Salomon, B.: Targeting anaplastic lymphoma kinase in lung cancer. *Clin Cancer Res*, 2011, 17, s. 2081–2085.
- 21 Rikova, K. – Guo, A. – Zeng, Q., et al.: Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. *Cell*, 2007, 131, s. 1190–1203.
- 22 Takeuchi, K. – Choi, Y. L. – Togashi, Y., et al.: KIF5B-ALK, a novel fusion oncogene identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. *Clin Cancer Res*, 2009, 15, s. 3143–3149.
- 23 Shaw, A. T. – Trap, B. Y. – Salomon, B. J., et al.: Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. *Lancet Oncol*, 2011, 12, s. 1004–1012.
- 24 Reck, M. – von Pawel, J. – Zatloukal, P., et al.: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAIL. *J Clin Oncol*, 2009, 27, s. 2415.
- 25 Reck, M.: Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after first-line chemotherapy: LUME Lung 1, a randomized, double-blind phase III trial. 2013, ASCO Annual Meeting, *J Clin Oncol*, 2013, 31, dopl.; abstrakt LBA8011.
- 26 Hanna, N.: LUME-Lung 2: A multicentre, randomized, double-blind, Phase III study of nintedanib plus pemetrexed vs. placebo plus pemetrexed in patients with advanced non-squamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. American Society of Clinical Oncology, Chicago, 2. 6. 2013. *J Clin Oncol*, 2013, 31, dopl.; abstrakt 8034.
- 27 Thatcher, N. – Hirsch, F. R. – Szczesna, A., et al.: A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). *J Clin Oncol*, 2014, 32, 5s (dopl.; abstrakt 8008).
- 28 Perol, M. – Ciuleanu, T. E. – Arrieta, O. – Prabhaskar, K. – Syrigos, K. N., et al.: REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy. *J Clin Oncol*, 2014, 32, 5s (dopl.; abstrakt LBA8006).

Nemalobuněčný karcinom plic s přestavbou genu EML4-ALK – nové možnosti léčby

prof. MUDr. Miloš Pešek, CSc. Klinika tuberkulózy a respiračních nemocí FN Plzeň
prof. Dr. med. Michael Hilker, FETCS Universitätsklinikum Regensburg, Německo
RNDr. Petr Grossmann FN Plzeň, Šiklův patologicko-anatomický ústav Plzeň

- 1 Bowler, D. W. – Weickhardt, A. J. – Doebele, R. C. – Camidge, D. R. – Jimeno, A.: Crizotinib for the treatment of patients with advanced non-small cell lung cancer. *Drugs of Today*, 2012, 48, s. 271–282.
- 2 Camidge, D. R. – Doebele, R. C.: Treating ALK-positive lung cancer – early successes and future challenges. *Nat Rev Clin Oncol*, 2012, 9, s. 268–277.
- 3 Pešek, M. – Grossmann, P. – Mukenšnabl, P. – Minářík, M.: První zkušenosti s vyšetřováním zlomu genu ALK (anaplastické lymfomové kinázy) a s podáním crizotinibu u vybraných nemocných s nemalobuněčnými karcinomy plic (NSCLC). *Studia Pneumologica Phthiseol*, 2012, 72, s. 159–162.
- 4 Ryška, A. – Petruželka, L. – Skříčková, J. – Kolek, V. – Hajduch, M. – Matěj, R. – Uvířová, M. – Pešek, M. – Dvořáčková, J. – Hornychová, H.: Interdisciplinární konsenzus pro prediktivní vyšetřování u nemalobuněčného karcinomu plic (NSCLC) – aktualizace 2012. *Studia Pneumologica Phthiseol*, 2012, 72, 3, s. 168.
- 5 Soda, M. – Choi, Y. L. – Enomoto, M., et al.: Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer. *Nature*, 2007, 448, s. 561–566.
- 6 Yang, J. – Zhang, X. – Su, J. – Chen, H. – Tian, H. – Juany, Y. – Xu, C. – Wu, Y. L.: Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. *Journal of Clin Oncol*, 2011, ASCO Annual Meeting Proceedings (post-Meeting Edition), 29, dopl., abstrakt 10517.

Možnosti systémové léčby gastroenteropankreatických neuroendokrinních tumorů

MUDr. Jiří Tomášek, Ph.D. Klinika komplexní onkologické péče MOÚ Brno, LF MU, Brno

- 1 Yao, J. C. – Hassan, M. – Phan, A., et al.: One hundred years after, "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. *J Clin Oncol*, 2008, 26, s. 3063–3072.
- 2 Rinke, A. – Miller, H. H. – Schade-Brittinger, C., et al.: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. *J Clin Oncol*, 2009, 27, s. 4656–4663.
- 3 Caplin, M. – Ruszniewski, P. – Pavel, M., et al.: A randomized, double-blind, placebo-controlled study of Lanreotide Antiproliferative Response in patients with gastroenteropancreatic NeuroEndocrine Tumors (CLARINET). European Cancer Congress, 2013, abstrakt 3, prezentováno 28. 9. 2013.
- 4 Klener, P. – Klener, P. Jr.: *Nová protinádorová léčiva a léčebné strategie v onkologii*. Praha, Grada Publishing, 2010.
- 5 Öberg, K. – Ferone, D. – Kaltsas, G., et al.: ENETS Consensus guidelines for the standards of care in neuroendocrine tumors: biotherapy. *Neuroendocrinology*, 2009, 90, s. 209–213.
- 6 Raymond, E. – Dahhan, L. – Raoul, J. L., et al.: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. *N Engl J Med*, 2011, 364, s. 501–513.
- 7 Faivre, S. – Nicolli, P. – Raoul, J. L., et al.: Updated overall survival analysis from a phase III study of sunitinib vs placebo in patients with advanced, unresectable pancreatic neuroendocrine tumor. ESMO Meeting, 2012, abstrakt 11550.
- 8 Yao, J. C. – Shah, M. H. – Ito, T., et al.: Everolimus for advanced pancreatic neuroendocrine tumors. *N Engl J Med*, 2011, 364, s. 514–523.
- 9 Pavel, M., et al.: Consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. *Neuroendocrinology*, 2012, 95, s. 157–176.

Gastrointestinální stromální tumor – základní algoritmus diagnostiky a léčby

MUDr. Zdeněk Linke Onkologická klinika FN Motol a 2. LF UK, Praha

- 1 Blanke, C. – Demetri, G., et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. *NEJM*, 2002, 347, s. 472–480.
- 2 Verweij, J. – Casali, P. G. – Zalcberg, J. – Le Cesne, A. – Reichardt, P. – Blay, J. Y.: Progression free survival in gastrointestinal stromal tumor with high a low dose imatinib: randomised trial. *Lancet*, 2004, 364, s. 1127–1134.
- 3 Rankin, C. – Von Mehren, M. – Blanke, C. – Benjamin, R. – Fletcher, C. D. M. – Bramwell, V.: Dose effect of imatinib in patients with metastatic GIST: Phase III Sarcoma Group Study 50033 (abstrakt 9005). *Proc ASCO*, 2004, 23, s. 815.
- 4 Van Glabbeke, M. – Verweij, J., et al.: Initial and late resistance to imatinib in advanced gastro-intestinal stromal tumor are predicted by different prognostic factors, an eortc-isg-agitg study. *J Clin Oncol*, 2005, 23, s. 5795–5804.
- 5 Blay, J. Y. – Le Cesne, A., et al.: Prospective multicenter randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: The French Sarcoma Group. *J Clin Oncol*, 2005, 23, s. 1107–1113.
- 6 Rios, M. – La Cesne, A., et al.: Interruption of imatinib in GIST patients with advanced disease after one year of treatment: Updated results of the prospective French Sarcoma Group randomized phase III trial on long term survival. *ASCO Ann Meet*, 2007, abstrakt 10016.
- 7 Van Glabbeke, M. M. – Lazar, K. – Rankin, C., et al.: Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analysis based on 1,640 patients. *ASCO Ann Meet*, 2007, abstrakt 10004.
- 8 Heindrich, M. C. – Maki, R. G. – Corless, C. L., et al.: Sunitinib response in imatinib-resistant GIST correlates with KIT and PDGFR mutation status. *J Clin Oncol*, 2006, 24, s. 9502.
- 9 Demetri, G. D. – van Oosterom, A. T., et al.: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. *Lancet*, 2006, s. 6736–6746.
- 10 Van Oosterom, A. T. – Dumez, H. – Desai, J., et al.: Combination signal transduction inhibition: A phase I/II trial of the oral m-TOR-inhibitor everolimus (E, RAD001) and imatinib mesylate in patients with gastrointestinal stromal tumors refractory to imatinib mesylate. *J Clin Oncol*, 2004, 22, s. 3002.
- 11 Demetri, G. D.: Inhibition of the Heat Shock Protein 90 (Hsp90) chaperone with the novel agent IPI-504 to overcome resistance to tyrosine kinase inhibitors (TKIs) in metastatic GIST: Updated results of a phase I trial. *ASCO Annual Meeting*, 2007, Sarcoma.
- 12 Von Mehren, M. – Reichardt, P. – Casali, P. G. – Blay, J.: A phase I study of AMN107 alone and in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST) – Study Update. *ASCO Meeting*, 2007.
- 13 Data on file, Novartis UK Ltd. Study No ST1571B2222. Open, randomized, phase II study of Gleevec in patients with unresectable or metastatic malignant gastrointestinal stromal tumors expressing c-kit. Report 15. 12. 2003.
- 14 Chandrajit, P. R. – DeMatteo, R. P.: Prognostic factors for primary GIST: prime time for personalized therapy? *Annals of Surgical Oncology*, 15, 1, s. 4–6.
- 15 De Matyck, R. P. – Antonescu, C. R., et al.: Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: Safety results from the U.S. Intergroup Phase II trial ACOSOG Z9000. *ASCO*, 2008.
- 16 De Matyck, R. P. – Owzar, K., et al.: Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. *ASCO*, 2008.
- 17 Zhan, W. H.: Efficacy and safety of adjuvant post-surgical therapy with imatinib in patients with high risk of relapsing GIST. *JCO*, 25, 18S.
- 18 Nilsson, B. – Sjolund, K. – Kindblom, L. C., et al.: Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). *Br J Cancer*, 2007, 96, s. 1656–1658.
- 19 Scandinavian Sarcoma Group: Study comparing 12 months versus 36 months of imatinib in the treatment of gastrointestinal stromal tumor (GIST). SSGXVIII/AIO. Dostupné z: <http://www.clinicaltrials.gov/ct/show/NCT00116935?order=1>, vyhledáno 25. 10. 2007.
- 20 European Organisation for Research and Treatment of Cancer: Imatinib mesylate or observation only in treating patients who have undergone surgery for localized gastrointestinal stromal tumor – EORTC-62024. Dostupné z: www.clinicaltrials.gov/ct/show/NCT00103168?order=1, vyhledáno 25. 10. 2007.
- 21 RTOG-S-0132 protocol. A phase II trial of neoadjuvant / adjuvant STI-571 (Gleevec NSC 716051) for primary and recurrent operable malignant GIST expressing the KIT receptor tyrosine kinase (CD117). Dostupné z: www.rtog.org/members/protocols/s0132/s0132.pdf, vyhledáno 3. 10. 2007.
- 22 Demetri, G. D. – Reichardt, P. – Kang, Y. K. – Blay, J. Y. – Joensuu, H. – Maki, R. G. – Rutkowski, P. – Hohenberger, P. – Gelderblom, H. – Leahy, M. G. – von Mehren, M. – Schöffski, P. – Blackstein, M. E. – Le Cesne, A. – Badalamenti, G. – Xu, J. M. – Nishida, T. – Laurent, D. – Kuss, I. – Casali, P. G., on behalf of GRID Investigators: Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): The GRID Trial.
- 23 Rutkowski, P. – Bylina, E. – Klimczak, T. – Switaj, T. – Limon, J., et al.: The outcome and predictive factors of sunitinib in advanced gastrointestinal stromal tumor (GIST) after imatinib failure—one institution study. *BMC Cancer*, 2012, 12, s. 107.
- 24 ENETS1: A randomized, open-label, multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with resectable or metastatic gastrointestinal stromal tumor (GIST). <http://clinicaltrials.gov/show/NCT00785785>.
- 25 An open-label, multi-center, single arm study to evaluate the efficacy of nilotinib in adult patients with metastatic or unresectable gastrointestinal stromal tumors in first line treatment. <http://clinicaltrials.gov/ct2/show/NCT00756509>.
- 26 Randomized phase III trial comparing nilotinib 800 mg imatinib 800 mg for the treatment of patients with advanced and/or metastatic gastrointestinal stromal tumor refractory to imatinib 400 mg. <http://clinicaltrials.gov/ct2/show/NCT00751036>.
- 27 A phase II, non-randomized, open-label multicenter study of 5 years adjuvant imatinib mesylate (Gleevec®) in patients at significant risk of recurrence following complete resection of primary gastrointestinal stromal tumor (GIST). <http://clinicaltrials.gov/ct2/show/NCT00867113>.
- 28 A phase II, open-label study of PTK787/ZK222584 in the treatment of metastatic gastrointestinal stromal tumors (GIST) resistant to imatinib mesylate. <http://clinicaltrials.gov/ct2/show/study/NCT00117299>.
- 29 Phase 2 study of oral AB1010 in non pre-treated, inoperable patients with locally advanced / metastatic gastro-intestinal stromal tumor (GIST). <http://clinicaltrials.gov/ct2/show/NCT00998751>.
- 30 An open-label study of AMG 706 in subject with advanced gastrointestinal stromal tumors (GISTs) who developed progressive disease or relapsed while on imatinib mesylate. <http://clinicaltrials.gov/ct2/show/NCT00089960>.
- 31 An open-label, phase II study to evaluate the biological activity of cediranib (AZD2171) as measured by (F 18) fluoro 2 deoxy d glucose – positron emission tomography (FDG-PET) response, in patients with metastatic gastro-intestinal stromal tumors (GISTs) resistant or intolerant to imatinib mesylate. <http://clinicaltrials.gov/ct2/show/study/NCT00385203>.
- 32 An phase II study of sorafenib in patients with metastatic or advanced gastrointestinal stromal tumors (GISTs) who failed to imatinib and sunitinib. <http://clinicaltrials.gov/ct2/show/NCT01091207>.
- 33 A study evaluating STA-9090 in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST). <http://clinicaltrials.gov/ct2/show/NCT010339519>.
- 34 Dasatinib first-line treatment in gastrointestinal stromal tumors. A multi center phase II trial. <http://clinicaltrials.gov/ct2/show/NCT00568750>.
- 35 Phase II study of crenolanib (CP-868,596), a selective and potent inhibitor of PDGFR, for the treatment of patients with advanced gastrointestinal stromal tumors with the D842-related mutations and deletions, including the D842V mutation, in the PDGFRA gene. <http://clinicaltrials.gov/ct2/show/NCT01243346>.
- 36 A study evaluating the safety, tolerability and pharmacokinetics of GDC-0973 in combination with GDC-0941 when administered daily in patients with locally advanced or metastatic solid tumor. <http://clinicaltrials.gov/ct2/show/NCT0133184>.
- 37 A study evaluating GDC-0980 administered once daily in patients with refractory solid tumors or non-Hodgkin's lymphoma. <http://clinicaltrials.gov/ct2/show/NCT000997765>.

Výběr optimální sekvence v léčbě metastatického renálního karcinomu

MUDr. Hana Študentová Onkologická klinika FN Olomouc

- Négrier, S. – Gratis, G. – Pérol, D., et al.: Temsirolimus and bevacizumab or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. *Lancet Oncol*, 2011, 12, s. 673–80.
- Bracarda, S. – Bellmunt, J. – Melichar, B., et al.: Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon- α 2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial.
- Motzer, R. J. – Barrios, C. H. – Kim, T. M., et al.: 1. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. *J Clin Oncol*, 2014, 32, s. 2765–2772.
- Steiner, F. – Chastonay, R. – Liewen, H., et al.: A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma. *Oncology*, 2012, 82, s. 333–340.
- Büchler, T. – Klappa, R. – Melichar, B., et al.: Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma—data from the Czech registry. *Ann Oncol*, 2012, 23, s. 395–401.
- Rini, B. I. – Escudier, B. – Tomczak, P., et al.: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. *Lancet*, 2011, 378, s. 1931–1939.
- Hutson, T. – Escudier, B. – Esteban, E., et al.: Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. *J Clin Oncol*, 2014, 32, s. 760–767.
- Motzer, R. J. – Escudier, B. – Oudars, S., et al.: Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. *Cancer*, 2012, 116, s. 4256–4265.
- Motzer, R. J. – Porta, C. – Vogelzang, N. J., et al.: Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. *Lancet Oncol*, 2014, 15, s. 286–96.
- Iacovelli, R. – Carteni, G. – Sternberg, C. N., et al.: Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort. *Eur J Cancer*, 2013, 49, s. 2134–2142.
- Busch, J. – Seidel, C. – Erber, B., et al.: Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma. *Eur Urol*, 2013, 64, s. 62–70.
- Calvani, N. – Morelli, F. – Chiuri, V., et al.: Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike? *Med Oncol*, 2013, 30, s. 578.
- Heng, D. Y. – Mackenzie, M. J. – Vaishampayan, U. N., et al.: Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. *Ann Oncol*, 2012, 23, s. 1549–1555.

Karcinom ovaria – současnost a novinky v léčbě

MUDr. Josef Chovanec, Ph.D. Oddělení gynekologické onkologie, MOÚ Brno

- ÚZIS ČR, NOR ČR 2013: Novotvary 2010 ČR.
- Vaughan, S. – Coward, J. I. – Bast Jr, R. C., et al.: Rethinking ovarian cancer: recommendations for improving outcomes. *Nat Rev Cancer*, 2011, 11, s. 719–725.
- Dundr, P.: Prekancerózy endometria, děložní tuby a ovaria: přehled současné problematiky. *Česko-slovenská patologie*, 2012, 1, s. 30–34.
- Ramirez, I. – Chon, H. S. – Apte, S. M.: The role of surgery in the management of epithelial ovarian cancer. *Cancer Control*, 2011, 18, 1, s. 22–30.
- du Bois, A. – Reuss, A. – Pujade-Lauraine, E., et al.: Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. *Cancer*, 2009, 115, 6, s. 1234–1244.
- Skirnisdóttir, I. – Sorbe, B.: Prognostic factors for surgical outcome and survival in 447 women treated for advanced (FIGO-stages III-IV) epithelial ovarian carcinoma. *Int J Oncol*, 2007, 30, s. 727–734.
- Harter, P. – du Bois, A. – Hahmann, M., et al.: Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. *Ann Surg Oncol*, 2006, 13, s. 1702–1710.
- Markman, M.: Pharmaceutical management of ovarian cancer: current status. *Drug*, 2008, 68, s. 771–789.
- Modesitt, S. C. – Jazaeri, A. A.: Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics. *Expert Opin Pharmacother*, 2007, 8, s. 2293–2305.
- Poveda, A. – Vergote, I. – Tjulandin, S., et al.: Trabectedin plus pegylated doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive subpopulation of OVA-301 Phase III randomized trial. *Ann Oncol*, 2011, 22, s. 39–48.
- Engelen, M. J. – Snel, B. J. – Schapveld, M., et al.: Long-term morbidity of adjuvant whole abdominal radiotherapy (WAPRT) or chemotherapy for early stage ovarian cancer. *Eur J Cancer*, 2009, 45, 7, s. 1193–1200.
- Burger, R. A. – Brady, M. F. – Bookman, M. A., et al.: Incorporation of bevacizumab in the primary treatment of ovarian cancer. *N Engl J Med*, 2011, 365, s. 2473–2483.
- Perren, T. J. – Swart, A. M. – Pfisterer, J. N., et al.: A phase 3 trial of bevacizumab in ovarian cancer. *N Engl J Med*, 2011, 365, s. 2484–2496.
- Seimetz, D.: Novel monoclonal antibodies for cancer treatment: The trifunctional antibody catumaxomab (Removab®). *J Cancer*, 2011, 2, s. 309–316.
- Poveda, A. – Ray-Coquard, I. – Romero, I., et al.: Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer. *Cancer Treatment Reviews*, 2014, 40, s. 366–375.

Stanovení strategie léčby u metastatického melanomu

MUDr. Eugen Kubala Klinika onkologie a radioterapie LF UK a FN Hradec Králové

- Chapman, P. B. – Hauschild, A. – Robert, C., et al.: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *N Engl J Med*, 2011, 364, s. 2507–2516.
- Hauschild, A. – Grob, J. J. – Demidov, L. V., et al.: Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. *Lancet*, 2012, 380, s. 358–365.
- Flaherty, K. T. – Puzanov, I. – Kim, K. B., et al.: Inhibition of mutated, activated BRAF in metastatic melanoma. *N Engl J Med*, 2010, 363, s. 809–819.
- Patel, J. D. – Krilov, L. – Adams, S., et al.: Clinical cancer advances 2013: annual report on progress against cancer from the American Society of Clinical Oncology. *J Clin Oncol*, 2014, 32, s. 129–160.
- Hauschild, A. – Grob, J. J. – Demidov, L. V., et al.: An update on BREAK-3, a phase III, randomized trial: dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). *J Clin Oncol*, 2013, 31, dopl., abstrakt 9013.
- Chapman, P. B. – Hauschild, A. – Robert, C., et al.: Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine in previously untreated patients with BRAF V600E mutated melanoma. *J Clin Oncol*, 2012, 30, dopl., abstrakt 8502.
- Ascierto, P. A. – Schadendorf, D. – Berling, C., et al.: MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: anon-randomised, open-label phase 2 study. *Lancet Oncol*, 2013, 14, s. 249–256.
- Flaherty, K. T. – Infante, J. R. – Daud, A., et al.: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. *N Engl J Med*, 2012, 367, s. 1694–1703.
- Eggermont, A., et al.: Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial. *J Clin Oncol*, 2014, 32, dopl. 5s, abstrakt 9008.
- Schadendorf, D. – Hodi, F. S. – Robert, C., et al.: Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. *Eur J Cancer*, 2013, 49, dopl., abstrakt 24LBA.
- Da Silva, I. – Perelman, R. O., et al.: Association of natural killer (NK) cell exhaustion with melanoma progression. *J Clin Oncol*, 2014, 32, dopl. 5s, abstrakt LBA9099.
- Ascierto, P. A. – Simone, E. – Giannarelli, D., et al.: Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. *J Transl Med*, 2012, 10, s. 107.
- Hodi, F. S., et al.: Long-term survival of ipilimumab-naïve patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. *J Clin Oncol*, 2014, 32, dopl. 5s, abstrakt 9002.
- Topalian, S. L. – Hodi, F. S. – Brahmer, J. R., et al.: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med*, 2012, 366, s. 2443–2454.
- Hamid, O. – Robert, C. – Daud, A., et al.: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. *N Engl J Med*, 2013, 369, s. 134–144.
- Weber, J. S. – Kudchadkar, R. R. – Yu, B., et al.: Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or naïve melanoma. *J Clin Oncol*, 2013, 31, s. 4311–4318.
- Atkins, M. B., et al.: Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma. *J Clin Oncol*, 2014, 32, dopl. 5s, abstrakt 9001.
- Segal, N. H., et al.: Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. *P J Clin Oncol*, 2014, 32, dopl. 5s, abstrakt 3002.
- Puzanov, I., et al.: Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (ipi) for V600E/Kmutation-positive unresectable or metastatic melanoma (MM). *J Clin Oncol*, 2014, 32, dopl. 5s, abstrakt 2511.
- Kudchadkar, R. R., et al.: A phase IB study of ipilimumab with peginterferon alfa-2b for patients with unresectable stages IIIb/C/IV melanoma. *J Clin Oncol*, 2014, 32, dopl. 5s, abstrakt 9098.
- Gajewski, T. F.: Molecular profiling of melanoma and the evolution of patient-specific therapy. *Semin Oncol*, 2011, 38, s. 236–242.
- Mesina, J. L. – Fenstermacher, D. A. – Eschrich, S., et al.: 12-chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? *Sci Rep*, 2012, 2, s. 765.
- Kudchadkar, R. – Gibney, G. – Sondak, V. K.: Integrating molecular biomarkers into current clinical management in melanoma. *Methods Mol Biol*, 2014, 1102, s. 27–42.
- Paraiso, K. H. – Smalley, K. S.: Making sense of MEK1 mutations in intrinsic and acquired BRAF inhibitor resistance. *Cancer Discov*, 2012,

Role parenterální výživy v podpůrné onkologické léčbě – nový pohled

MUDr. Petr Beneš Interní oddělení, Nemocnice Na Homolce, Praha

- 1 The Veterans Affairs Total Parenteral Nutrition Cooperative Study Group: Perioperative total parenteral nutrition in surgical patients. *N Engl J Med*, 1991, 325, s. 525–532.
- 2 Thorell, A. – Nygren, J. – Ljungqvist, O.: Insulin resistance: a marker of surgical stress. *Curr Opin Clin Nutr Metab Care*, 1999, 2, s. 69–78.
- 3 Gianotti, L. – Braga, M. – Nespoli, L., et al.: A randomized controlled trial of preoperative oral supplementation with a specialized diet in patients with gastrointestinal cancer. *Gastroenterology*, 2002, 122, s. 1763–1770.
- 4 Prado, C. M. M. – Baracos, V. E. – McGargar, V. J., et al.: Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. *Clin Cancer Res*, 2007, 13, s. 3264–3268.
- 5 Ries, A. – Trottenberg, P. – Elsner, F., et al.: A systematic review on the role of fish oil for the treatment of cachexia in advanced cancer: An EPCRC cachexia guidelines project. *Palliative Med*, 2012, 26, s. 294–304.
- 6 Shils, M. E. – Wright, W. L. – Turnbull, A. – Brescia, F.: Long-term parenteral nutrition through an external arteriovenous shunt – report of a case. *N Engl J Med*, 1970, 283, s. 341–344.
- 7 Anděl, M. – Filip, K. – Brůček, P.: Dlouhá domácí parenterální výživa cestou totálně implantovaného kanylovaného systému. *Čas Lék Čes*, 1992, 131, s. 395–298.
- 8 Bozzetti, F. – Cozzaglio, L. – Biganzoli, E., et al.: Quality of life and length of survival in advanced cancer patients on home parenteral nutrition. *Clin Nutr*, 2002, 21, s. 281–288.
- 9 Gozzaglio, L. – Balzola, F. – Cosentino, F., et al.: Outcome on cancer patients receiving home parenteral nutrition. *J Parenter Enteral Nutr*, 1997, 21, s. 339–342.
- 10 Scolapio, J. S. – Picco, M. F. – Tarrosa, V. B.: Enteral versus parenteral nutrition: the patient's preference. *J Parenter Enteral Nutr*, 2002, 26, s. 248–250.

Novinky v léčbě průlomové bolesti

MUDr. Marek Hakl, Ph.D. Centrum pro léčbu bolesti ARK LF MU a FN u sv. Anny v Brně

- 1 Hakl, M. – Hřib, R.: Farmakoterapie léčby onkologické bolesti. *Interní medicína pro praxi*, 2007, 9, s. 229–300.
- 2 Kabelka, L. – Kozák, J. – Lejčko, J. – Sláma, O.: Doporučený postup pro léčbu průlomové bolesti. *Bolest*, 2011, 14, dopl. 1.
- 3 Webster, L. R.: Breakthrough pain in the management of chronic persistent pain syndromes. *Am J Manag Care*, 2008, 14, s. 116–122.
- 4 Dickman, A.: Integrated strategies for the successful management of breakthrough cancer pain. *Curr Opin Support Palliat Care*, 2011, 5, s. 8–14.
- 5 Fortner, B. V. – Okon, T. A. – Portenoy, R. K.: A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. *J Pain*, 2002, 3, s. 38–44.
- 6 Bredenberg, S. – Duberg, M. – Lennernas, B., et al.: In vitro and in vivo evaluation of new sublingual tablet system for rapidoromucosal absorption using fentanyl citrate as the active substance. *Eur J Pharm Sci*, 2003, 20, s. 327–334.
- 7 Darwish, M. – Kirby, M. – Jiang, J. G.: Effect of buccal dwell time on the pharmacokinetic profile of fentanyl buccal tablet. *Expert Opin Pharmacother*, 2007, 8, s. 2011–2016.
- 8 Darwish, M. – Tempero, K. – Kirby, M., et al.: Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers. *Clin Pharmacokinet*, 2005, 44, s. 1279–1286.
- 9 Davis, M.: Fentanyl pro breakthrough pain: a systematic review. *Expert Rev Neurother*, 2011, 11, s. 1197–1216.

Qutenza v léčbě chemoterapií indukované polyneuropatie

MUDr. Marek Hakl, Ph.D. Centrum pro léčbu bolesti ARK LF MU a FN u sv. Anny v Brně

- 1 Ehler, E.: Neuropatická bolest u diabetické polyneuropatie. *Neurologie pro praxi*, 2010, 11, s. 107–111.
- 2 Attal, N. – Cruccu, G. – Baron, R. – Haanpaa, M. – Hanson, P. – Jensen, T. – Numikko, T.: EFNS guidelines on the pharmacological treatment of neuropathic pain: 2009 revision. *European Journal of Neurology*, 2009, 8, s. 1010–1018.
- 3 Backonja, M. – Wallace, M. – Blonsky, R. – Cutler, B., et al.: NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. *Lancet Neurol*, 2008, 7, s. 1106–1112.
- 4 Simpson, D. – Brown, S. – Tobias, J.: Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. *Neurology*, 2008, 70, s. 2305–2313.

HPV infekce u mužů

doc. MUDr. Tomáš Fait, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a VFN Praha

- 1 European Centre for Disease Prevention and Control: *Introduction of HPV vaccines in EU countries – an update*. Stockholm, ECDC, 2012.
- 2 Fait, T. – Dvořák, V. – Skřivánek, A., et al.: Epidemiologie genitálních bradavic mezi ženami v ČR. *Čes Gynek*, 2012, 77, 4, s. 360–363.
- 3 Fenton, K. A. – Lowndes, C. M.: Recent trends in the epidemiology of STI in the European Union. *Sex Trans Infect*, 2004, 80, s. 255–263.
- 4 Desai, S. – Wetten, S. – Woodhall, S. C., et al.: Genital warts and cost of care in England. *Sex Trans Infect*, 2011, 87, 6, s. 464–468.
- 5 Garland, S. M. – Hernandez-Avila, M. – Wheeler, C. M., et al.: Quadrivalent vaccine against human papillomavirus to prevent anogenital disease. *NEJM*, 2007, 356, s. 1928–1943.
- 6 Fairley, C. K. – Hocking, J. S. – Gurrin, L. C., et al.: Rapid decline in presentation of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. *Sex Transm Infect*, 2009, 85, s. 499–502.
- 7 Gertig, D. M. – Brotherton, J. M. – Saville, M.: Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia. *Sex Health*, 2011, 8, 2, s. 171–178.
- 8 Gallagher, T. Q. – Derkay, C. S.: Recurrent respiratory papillomatosis. *Curr Opin Otolaryngol Head Neck Surg*, 2008, 16, s. 645–655.
- 9 Dubová, J. – Vydrová, J. – Bendová, O., et al.: Výsledky vakcinace proti HPV u pacientů s rekurentní papilomatózou hrtanu. *Prostrad Med*, 2012, 13, s. 921–923.
- 10 D'Sousa, G. – Kreimer, A. – Viscidi, R., et al.: Case-control study of human papillomavirus and oropharyngeal cancer. *NEJM*, 2007, 356, s. 1944–1956.
- 11 Gillison, M. L. – Broutian, T. – Pickard, R. K., et al.: Prevalence of oral HPV infection in the United States, 2009–2010. *JAMA*, 2012, 307, s. 693–703.
- 12 Giuliano, A. R. – Palefsky, J. M. – Goldstone, S., et al.: Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. *N Engl J Med*, 2011, 364, 5, s. 401–411.
- 13 Palefsky, J. M. – Giuliano, A. R. – Goldstone, S., et al.: HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. *N Engl J Med*, 2011, 365, s. 1567–1585.